Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

If you’re living with diabetes, learn why you may be at greater risk for opioid use (and misuse) and what to do about it.

Three cities in Hawaii, Minnesota, and Texas report the highest usage of injectable weight loss medications. Meanwhile, ...

Discover ADM's new solutions platform for GLP-1 consumers. With over 25 market-ready concepts, it assists those on ...

A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show. Workers will ...

The report, published as part of the National Program for Quality Indicators in Community Healthcare for 2023, points to the ...

An obesity expert weighs in on intriguing new data and new drugs that hold promise in the battle against a stubborn problem.

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...